Cybin Inc (CYBN) Stock Price, Quote & News

Company Profile

Cybin Inc., a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical...

Industry: Biotechnology

Sector: Healthcare

Website: cybin.com

Address:

100 King Street West, Suite 5600, Toronto, Canada

DJS777 Dec. 13 at 4:42 PM

$CYBN RFK Jr will cut prescription drugs and increase weed and psychedelics accesshttps://www.theguardian.com/us-news/2024/nov/25/rfk-jr-prescription-drugs-cannabis-psychedelics?hl=en-GB LFG

0 · Reply

Sticktwit Dec. 13 at 4:39 PM

$CYBN https://www.facebook.com/share/r/1BUpJeVQ3z/

0 · Reply

BinaryLogic Dec. 13 at 11:07 AM

$CYBN Overlooked and Undervalued, CYBN will likely ride the momentum of possible Schedule-1 for CBD (IMO), as psychedelic therapeutics would be a possible extension thereafter to CBD Schedule-1 re-classification. The stock has been trading at/around an ATL, it has more than sufficient Cash to support Operations intermediate term and multiple catalysts stacked/upcoming beyond possible Schedule-1 consideration.

0 · Reply

Astrowen Dec. 12 at 7:58 PM

$CYBN hey I’m back to green again

0 · Reply

nataliecruz07 Dec. 12 at 6:54 PM

$CYBN psychedelic and mental health exposure, binary regulatory and clinical path with outsized response to each milestone

0 · Reply

BobJohnBuoy666 Dec. 12 at 6:47 PM

$CYBN well well well

0 · Reply

Mastacash Dec. 12 at 6:07 PM

$CYBN wait til the volume comes in. You ain’t seen nothing yet…

0 · Reply

Alex1710 Dec. 12 at 6:03 PM

$CYBN It is a take over bid candidate.

0 · Reply

microdoseme Dec. 12 at 6:02 PM

$CYBN https://open.substack.com/pub/themicrodose/p/federal-legislators-try-again-on?utm_campaign=post&utm_medium=web

0 · Reply

Alex1710 Dec. 12 at 5:11 PM

$CYBN What a beautiful stock. IMO they don't need a new CEO

0 · Reply

Cybin Inc. (CYBN) Q2 2026 Earnings Call Transcript

Nov 13, 2025, 7:20 AM EST - 4 weeks ago

Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

Nov 12, 2025, 7:30 AM EST - 4 weeks ago

Cybin to Participate in the Jefferies Global Healthcare Conference in London

Nov 6, 2025, 7:30 AM EST - 5 weeks ago

Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025

Nov 5, 2025, 7:30 AM EST - 5 weeks ago

Cybin to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Nov 3, 2025, 7:30 AM EST - 5 weeks ago

Cybin to Participate at the 2025 Milken Institute Future of Health Summit

Oct 31, 2025, 4:19 PM EDT - 6 weeks ago

Cybin Announces Closing of $175 Million Registered Direct Offering

Oct 28, 2025, 8:00 AM EDT - 6 weeks ago

Cybin Announces $175 Million Registered Direct Offering

Oct 21, 2025, 8:00 AM EDT - 7 weeks ago

BetterLife Pharma Appoints Doug Drysdale as Corporate Advisor

Sep 23, 2025, 5:00 PM EDT - 2 months ago

Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones

Sep 11, 2025, 3:59 PM EDT - 3 months ago

CYBN Investors Have Opportunity to Join Cybin Inc. Fraud Investigation with the Schall Law Firm

Sep 11, 2025, 7:30 AM EDT - 3 months ago

Cybin to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Sep 8, 2025, 7:30 AM EDT - 3 months ago

Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder

Sep 4, 2025, 7:30 AM EDT - 3 months ago

Cybin to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 7:30 AM EDT - 3 months ago

Cybin to Participate in the Cantor Global Healthcare Conference 2025

Sep 2, 2025, 7:30 AM EDT - 3 months ago

Cybin Announces Senior Leadership Changes

Aug 26, 2025, 7:30 AM EDT - 3 months ago

Cybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Aug 18, 2025, 5:30 PM EDT - 4 months ago

Cybin Announces Results of Annual Meeting of Shareholders

Aug 13, 2025, 5:30 PM EDT - 4 months ago

Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results

Aug 7, 2025, 7:30 AM EDT - 4 months ago

Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Aug 6, 2025, 7:30 AM EDT - 4 months ago

Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference

Jul 17, 2025, 7:30 AM EDT - 5 months ago

Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Jul 1, 2025, 11:19 AM EDT - 5 months ago

REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Jun 30, 2025, 10:03 PM EDT - 5 months ago

Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights

Jun 30, 2025, 9:27 PM EDT - 5 months ago

Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Jun 13, 2025, 7:45 AM EDT - 6 months ago

Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics

Jun 12, 2025, 7:30 AM EDT - 6 months ago

Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference

Jun 11, 2025, 7:30 AM EDT - 6 months ago

Cybin to Participate in the 2025 Psychedelic Science Conference

Jun 3, 2025, 7:30 AM EDT - 6 months ago

Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder

May 22, 2025, 7:30 AM EDT - 7 months ago

Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025

May 20, 2025, 7:30 AM EDT - 7 months ago

Cybin Applauds FDA Commissioner Dr. Martin Makary's Call to Accelerate and Prioritize Research on Psychedelic Therapeutics

May 15, 2025, 7:30 AM EDT - 7 months ago

Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder

May 14, 2025, 7:30 AM EDT - 7 months ago

Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase

May 8, 2025, 7:30 AM EDT - 7 months ago

Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder

May 1, 2025, 7:30 AM EDT - 8 months ago

Cybin to Participate at the 28th Annual Milken Institute Global Conference

Apr 23, 2025, 7:30 AM EDT - 8 months ago

Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003

Apr 21, 2025, 8:00 AM EDT - 8 months ago

Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs

Feb 10, 2025, 9:48 PM EST - 10 months ago

Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights

Jan 15, 2025, 12:07 PM EST - 11 months ago

Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Jan 13, 2025, 7:30 AM EST - 11 months ago

Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025

Jan 9, 2025, 5:00 PM EST - 1 year ago

Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Dec 10, 2024, 7:30 AM EST - 1 year ago

Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results

Dec 4, 2024, 7:30 AM EST - 1 year ago

Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024

Nov 18, 2024, 7:00 AM EST - 1 year ago

Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder

Nov 14, 2024, 7:30 AM EST - 1 year ago

Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024

Nov 13, 2024, 7:30 AM EST - 1 year ago

Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results

Oct 31, 2024, 7:30 AM EDT - 1 year ago

Cybin to Participate at the 2024 Milken Institute Future of Health Summit

DJS777 Dec. 13 at 4:42 PM

$CYBN RFK Jr will cut prescription drugs and increase weed and psychedelics accesshttps://www.theguardian.com/us-news/2024/nov/25/rfk-jr-prescription-drugs-cannabis-psychedelics?hl=en-GB LFG

0 · Reply

Sticktwit Dec. 13 at 4:39 PM

$CYBN https://www.facebook.com/share/r/1BUpJeVQ3z/

0 · Reply

BinaryLogic Dec. 13 at 11:07 AM

0 · Reply

Astrowen Dec. 12 at 7:58 PM

$CYBN hey I’m back to green again

0 · Reply

nataliecruz07 Dec. 12 at 6:54 PM

$CYBN psychedelic and mental health exposure, binary regulatory and clinical path with outsized response to each milestone

0 · Reply

BobJohnBuoy666 Dec. 12 at 6:47 PM

$CYBN well well well

0 · Reply

Mastacash Dec. 12 at 6:07 PM

$CYBN wait til the volume comes in. You ain’t seen nothing yet…

0 · Reply

Alex1710 Dec. 12 at 6:03 PM

$CYBN It is a take over bid candidate.

0 · Reply

microdoseme Dec. 12 at 6:02 PM

$CYBN https://open.substack.com/pub/themicrodose/p/federal-legislators-try-again-on?utm_campaign=post&utm_medium=web

0 · Reply

Alex1710 Dec. 12 at 5:11 PM

$CYBN What a beautiful stock. IMO they don't need a new CEO

0 · Reply

Bbbb44444 Dec. 12 at 3:55 PM

$ATAI and $CYBN have the advantage imo, even if they’re not first mover. Clinics, insurers, and psychiatrists favor shorter sessions, lower staffing, and predictable experiences (non-hallucinogenic). That strongly favors CYBN and ATAI over time, even if $CMPS gets there first.

2 · Reply

Mastacash Dec. 12 at 3:48 PM

$CYBN stock is going to triple in a short period of time imo. It will close the gap with sector peers. 900million market cap does not seem far fetched at all. They have funding and dumped the toxic converts. Science and IP is solid. With new regulation a seasoned CEO could be on the way.

0 · Reply

grumpygoose Dec. 12 at 3:00 PM

$CYBN Major resistance, need to pooosshhhh

0 · Reply

tomtom101 Dec. 12 at 12:51 AM

$CYBN CEO Management needs to talk to Trump Admin. Psychedelics for treatment of mental health.

1 · Reply

Mastacash Dec. 12 at 12:00 AM

$CYBN big news from the White House. Rolling back marijuana restrictions to schedule 3. Bullish for all psychedelics, you know shrooms is next. Wouldn’t be surprised to see big pharma come sniffing around the sector to pick up some of this IP to get ahead of any regulation.

0 · Reply

Mastacash Dec. 11 at 8:41 PM

$CYBN been watching this price action and order book all day. Big buyers coming in, buying at the market. Just saw 6k shares sitting at 6.30 get gobbled up quickly. Little pathetic sells trying to push the stock down most likely short sellers, it’s been their game plan forever, they wait until volume dies down and smack the bid with a few hundred shares. Someone wants in this time..

1 · Reply

BelieveinthePK Dec. 11 at 6:51 PM

$CYBN Agree, way long on this position. Back above $35 at least this time next year.

0 · Reply

Mastacash Dec. 11 at 6:06 PM

$CYBN 2026 is make or break year for the sector, numerous phase 2 and 3 readings, most companies are well capitalized going into next year. $CYBN being the lagger but imo has equal value of peers, has the most upside potential. With the Fed essentially pumping liquidity into the system again, watch for small spec names to catch a bid into next year.

0 · Reply

ProfitMaker4 Dec. 11 at 4:17 PM

$CYBN Increased my long position sub $6 earlier this week. Strong financials and severely undervalued at these levels.

0 · Reply

Joe_Twit Dec. 11 at 3:35 PM

$CYBN anybody know what's going on here? It feels like $CYBN is getting ready to run. The price-per-pound for premium IP beats $MNMD and $CMPS IMO

0 · Reply

wifesboyfriends Dec. 11 at 3:30 PM

$CYBN why though?

1 · Reply

cacci11 Dec. 11 at 3:22 PM

$CYBN up 5% an hour into trading day. Not a single word here? What gives?

0 · Reply

Market Cap	168.26M
Revenue (ttm)	0.00
Net Income (ttm)	-81.31M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	898,400
Avg Vol	835,252
Day's Range	N/A - N/A
Shares Out	25.19M
Stochastic %K	88%
Beta	0.67
Analysts	Strong Sell
Price Target	$45.00